Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Studies from S. Yoshida and co-authors have provided new information about bladder cancer
May 13th, 2008
According to recent research published in the journal Bju International, "To investigate the effect of C-reactive protein (CRP) level on the prognosis of patients with muscle-invasive bladder cancer treated with chemoradiotherapy (ChRT), as it is increasingly recognized that the presence of a systemic inflammatory response is associated with poor survival in various malignancies. The clinical records of 88 patients with bladder urothelial carcinoma (cT2-4 N0M0) treated with ChRT were reviewed retrospectively." "ChRT comprised external beam radiotherapy to the bladder (40 Gy) with two cycles of cisplatin (50-100 mg) at 3-week intervals. Elevated CRP was defined as...
Source: Cancer Weekly (2008-05-13)
|
